anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Risk Summary

Based on its mechanism of action, XOLREMDI is expected to cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)] . There are no available data on XOLREMDI use in pregnant women informing the risk of embryo-fetal developmental toxicities. Animal models link reductions in CXCR4/SDF-1 signaling to adverse outcomes in mammalian embryo-fetal development (see Data) . No definitive animal studies have been conducted to evaluate the effect of mavorixafor on reproduction and fetal development. 

Advise pregnant women of the potential risk to the fetus and to use effective contraception [see Warnings and Precautions (5.1)and Use in Specific Populations (8.3)] . 

The estimated background risk of major birth defects and miscarriages for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

Animal reproduction studies have not been conducted with mavorixafor to evaluate effects on reproduction and embryo-fetal development. CXCR4/SDF-1 signaling plays an important role in mammalian embryo-fetal and placental development. In mice, CXCR4-/- knockout is embryo lethal and causes multiple developmental toxicities, most notably in the hematopoietic, cardiovascular and nervous systems. CXCR4/SDF-1 levels have a key role in stimulating trophoblast proliferation and differentiation necessary for appropriate placental growth and function in humans [see Warnings and Precautions (5.1)].
The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction. The drug will taken 3 times 490 mg per day for 7 days. Wash out period before enter another arm is 7 days.
PURPOSE:To heat-treat an aqueous solution containing a blood coagulation factor VIII derived from a human in the presence of a main stabilizer, e.g. a neutral amino acid or monosaccharide, and a specific assistant stabilizer at a specific temperature for given time. CONSTITUTION:An aqueous solution containing a blood coagulation factor VIII derived from a human is heat-treated at 50-80 deg.C to prevent the infection with hepatic viruses. In the process, the heat treatment is carried out in the presence of 10-60(W/V)% main stabilizer selected from a neutral amino acid, e.g. glycine or alanine, a monosaccharide, e.g. glucose or xylose, an oligosacchairide, e.g. maltose or sucrose, or a sugaralcohol, e.g. mannitol, and 10-30(W/V)% assistant stabilizer selected from a salt of a 3-10C organic carboxylic acid for 3-15hr. The activity of the coagulation factor VIII contained in the aqueous solution in the heat treatment is preferably 1-50units/ml. The pH of the aqueous solution is 5-10, preferably 6.0-8.0.
PURPOSE:To obtain tea of Gynostemma pentaphyllum Makino, having better quality and flavor than those of the conventional products, causing relatively little decomposition of active constituents, and useful as a health drink and decoction, by roasting dried Gynostemma pentaphyllum Makino. CONSTITUTION:Gynostemma pentaphyllum Makino is forced to dry preferably at 30-70 deg.C, and the above-mentioned dried material is roasted preferably at 100- 170 deg.C to give the aimed tea of Gynostemma pentaphyllum Makino. Products obtained by the conventional drying have disadvantages in quality and flavor as follows; strong bitterness, grassy smell and easy growth of molds. The roasting of the dried Gynostemma pentaphyllum Makino has been lately found to give the aimed tea, having strong sweetness, little bitterness and good fragrance, and very suitable for a drink and aqueous solution. The tea has advantages as follows; Active constituents are sufficiently contained, and molds scarcely grow. Deterioration in quality is not caused even by preservation, etc.
Iopamidol Injection may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms.

Sites of active infection may also be enhanced following contrast media administration.

Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool.

Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation.
Hemorrhagic shock (HS) is a life-threatening condition with high mortality rates despite current treatments. This study investigated whether targeted temperature management (TTM) could improve outcomes by modulating inflammation and protecting organs following HS. Using a rat model of HS, TTM was applied at 33°C and 36°C after fluid resuscitation. Surprisingly, TTM at 33°C increased mortality, while TTM at 36°C significantly improved survival rates. It also reduced histological damage in lung and kidney tissues, lowered serum lactate levels, and protected against apoptosis and excessive reactive oxygen species production. TTM at 36°C inhibited the release of high mobility group box 1 protein (HMGB1), a key mediator of inflammation, and decreased proinflammatory cytokine levels in the kidneys and lungs. Moreover, it influenced macrophage behavior, suppressing the harmful M1 phenotype while promoting the beneficial M2 polarization. Cytokine array analysis confirmed reduced levels of proinflammatory cytokines with TTM at 36°C. These results collectively highlight the potential of TTM at 36°C as a therapeutic approach to improve outcomes in HS. By addressing multiple aspects of injury and inflammation, including modulation of macrophage responses and cytokine profiles, TTM at 36°C offers promising implications for critical care management after HS, potentially reducing mortality and improving patient recovery.
Propafenone is highly metabolized by the liver. Severe liver dysfunction increases the bioavailability of propafenone to approximately 70% compared with 3% to 40% in patients with normal liver function when given RYTHMOL immediate-release tablets. In 8 patients with moderate to severe liver disease administered RYTHMOL immediate-release tablets, the mean half-life was approximately 9 hours. No trials have compared bioavailability of propafenone from RYTHMOL SR in patients with normal and impaired hepatic function. Increased bioavailability of propafenone in these patients may result in excessive accumulation. Carefully monitor patients with impaired hepatic function for excessive pharmacological effects [see Overdosage (10)].
Targeting contrast agent for magnetic resonance imaging (MRI). In preferred embodiments, self-assembled polyelectrolytes coated superparamagnetic iron oxide contrast agent particles are provided, which are labeled with targeting moieties, afforded enhanced relaxivity, improved signal-to-noise and targeting ability. Accordingly, the invention relates to a stable targeting contrast nanosystem applicable for magnetic resonance imaging (MRI) having at least one nanoparticle polyelectrolyte polyanion; a targeting agent conjugated to the biopolymer; and a superparamagnetic ligand. In another embodiment the nanosystem according to the invention has at least two biocompatible and biodegradable nanoparticle polyelectrolyte biopolymer. Particularly, the superparamagnetic iron oxide particles are coated by a polyelectrolyte biopolymer and this system self-assembles with the other biopolymer to produce stable nanosystem for magnetic resonance imaging. Targeting moieties are conjugated to a biopolymer or to the self-assembled biopolymers to realize a targeted delivery of contrast agent. Methods for making these targeting MRI contrast agents are also provided.
In the context of blindness, studies on the recognition of facial expressions of emotions by touch are essential to define the compensatory touch abilities and to create adapted tools on emotions. This study is the first to examine the effect of visual experience in the recognition of tactile drawings of facial expressions of emotions by children with different visual experiences. To this end, we compared the recognition rates of tactile drawings of emotions between blind children, children with low vision and sighted children aged 6-12 years. Results revealed no effect of visual experience on recognition rates. However, an effect of emotions and an interaction effect between emotions and visual experience were found. Indeed, while all children had a low average recognition rate, the drawings of fear, anger and disgust were particularly poorly recognized. Moreover, sighted children were significantly better at recognizing the drawings of surprise and sadness than the blind children who only showed high recognition rates for joy. The results of this study support the importance of developing emotion tools that can be understood by children with different visual experiences.
A combined immunotherapy against cancer and infectious diseases. A combination comprising an immune checkpoint antibody and a fusion protein is disclosed. The fusion protein comprises: a CD 40-binding domain, an antigen, a translocation domain between the CD 40-binding domain and the antigen, and a furin (furin) and/or cathepsin (cathepsin) L cleavage site between the CD 40-binding domain and the translocation domain. The antigen is an antigen of a pathogen or a tumor antigen. Furin and/or cathepsin L cleavage sites may disengage the CD 40-binding domain from the fusion protein. The combinations of the invention are effective in eliciting antigen-specific cell-mediated immune responses, which are suitable for treating tumors and/or diseases caused by pathogens in an individual in need thereof.
873,151. Digital data storage apparatus. INTERNATIONAL BUSINESS MACHINES CORPORATION. Jan. 15, 1958 [Jan. 15, 1957], No. 1449/58. Class 106 (1). An electric transferring device comprises a data storage unit having a plurality of storage positions each adapted to store an item of data, read-out means associated with each storage position and adapted when energized to cause the associated position to deliver an output representative of the item of data stored therein, scanning means adapted successively to energize separate selected groups of said readout means, said groups including a selectable predetermined number of storage positions, and data receiving means adapted to receive data delivered from each group, including a further storage unit having a number of storage positions equal to the maximum of the selectable predetermined number. An arrangement is described for reading-out a three-dimensional core matrix comprising seven planes each similar to that shown in Fig. 17. The complete matrix (120 characters) is read in 14 print cycles 9 characters being read in each of the first 8 cycles and 8 in each of the remaining 6 cycles. Within each cycle data is read-out serially by character and parallel by bit to a thyratron register 10 and then to a printer having 9 type bars so arranged that a complete line of 120 characters is printed in 14 interlaced printings. That is during the first printing cycle characters 0, 14, 28, 42 ... 112 are printed, during the second cycle characters 1, 15, 29, 43 ... 113, are printed and so on for the other cycles. The cores of the plane shown, Fig. 17, are numbered consecutively from 0 to 119 starting at the top left (intersection of row L0 and column C0) and progressing down each column in turn. Readout of the matrix is achieved by control pulses from a ring timing device (Fig. 7, not shown) which are routed via either an arrangement of relay contacts (Figs. 11, 12, 13, not shown) or an arrangement of triode gates (Fig. 19, not shown) which ensure that the cores are read in the required order. Specification 847,480 is referred to.
Participants will receive treatment as usual and be informed of the official physical activity guidelines as part of the information on group allocation. Moreover, they will be advised to continue their daily living, as they normally would do, not guiding them to other interventions neither preventing them to do so. In addition, participants in the usual care group will be given a subsidized membership including access to the exercise classes for four months after the 12 months follow up.
Aging is associated with progressive loss of functional reserve in all organ systems. For most people, physiologic compensation for age-related changes is adequate. However, it is easy to decompensate under stressful circumstances, such as surgery and illness. Under the specific physiologic phenomenon, geriatric anesthesia is acquired for more intensive monitoring. In Taiwan, about 75.92% of the elderlies above 65 years old suffered from chronic diseases or major diseases, especially in circulatory system. Thus, dramatic hemodynamic change is often observed in surgeries in this population. For the elderlies with fracture are more vulnerable to have complications, poor prognosis and decompensated organ functions.

In our daily practice, the surgeries for fracture in lower extremities can performed under either general anesthesia or regional anesthesia, such as spinal anesthesia epidural anesthesia, and nerve block. The anesthetic method is determined under each patient's condition. EKG, arterial catheter, pulse oximeter are usually basic for intra-operative monitoring. However, these tools are unable to inform us the real-time cardiac output and the exact status of tissue perfusion. Nowadays, there are many non-invasive instruments able to estimate more detailed hemodynamic parameters, which are very crucial during anesthesia.1 But these instruments are not widely used in our daily practices. We need more researches to support the beneficial roles of these non-invasive monitors to high-risk patients during surgery.

Due to the hemodynamic feature in elderlies, we will use conventional measurements as EKG, arterial blood pressure and pulse oximeter. To measure the perfusion of the lower extremities, we use a relative new tool, the non-invasive transcutaneous near infrared spectroscopy (NIRS).2,3 NIRS was used as the cerebral oximetry to measure the tissue perfusion of the cerebral cortex. It uses reflectance oximetry to measure the oxygen saturation of the tissue underneath the sensor.1 Recently, NIRS has been proved not only to continuously monitor tissue oxygenation saturation (StO2) continuously, but also to predict the patient's poor prognosis.3,4 To measure the cardiac output intra-operatively, we will use the non-invasive cardiac output monitor (NICOM®, Cheetah). Bioreactance technique allows the measurement of hemodynamic changes via four electrodes placed on the thorax. The electrical current crossing the thorax makes "signal phase shift", which is related to changes in the volume of the thoracic aorta. Thus, the volume change in the thoracic aorta is able to estimate stroke volume.1,5 Postoperative prognosis is adjusted with the recovery of ambulation, the duration of ICU stay, the morbidity and mortality, and the questionnaire (SF-36) about quality of life.
Type 1 diabetes (T1D) is the end result of immune mediated beta-cell destruction. It is generally accepted that at the time of T1D is diagnosed, an individual has lost most (60-80%) of his/her beta cell function. The loss of insulin-producing beta cells is believed to occur over a period of months to years and individuals can retain some endogenous insulin production even years after clinical diagnosis of diabetes. The presence of residual beta cell mass may signify a complex interplay between the auto-destructive immune response and the capacity for limited beta cell regeneration. When initiated at T1D onset, immunosuppression has been shown to preserve beta cell function, but with significant and limiting toxicities. Selectively targeting the pathogenic T-cells involved in T1D development and progression could achieve the same objective with less toxicity. Various studies of the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes have demonstrated that administering glutamic acid decarboxylase (GAD65), a beta cell autoantigen, can prevent the immune destruction and delay or prevent diabetes onset. Preclinical studies have also identified several growth factors, including epidermal growth factor (EGF), glucagon-like peptide 1 (GLP-1), and gastrin, that appear to promote beta cell proliferation. We seek to test the potential for preserving beta cell function early in the disease course of T1D by combining antigen-specific immunomodulation with regenerative stimuli.
Children with Cerebral Palsy. Motor imagery training group will receive a traditional physiotherapy and motor imagery training within a specific program, two days a week for a total of 8 weeks (30 minutes traditional physiotherapy session+15 minutes MI training). The motor imagery training will be designed for the individual basis with standard protocols. All sessions will be performed in the clinic.
Safety and effectiveness in the pediatric population have not been established (see BOX WARNING and WARNINGS—Clinical Worsening and Suicide Risk).

Anyone considering the use of phenelzine sulfate in a child or adolescent must balance the potential risks with the clinical need.

Phenelzine sulfate, as with other hydrazine derivatives, has been reported to induce pulmonary and vascular tumors in an uncontrolled lifetime study in mice.

In depressed patients, the possibility of suicide should always be considered and adequate precautions taken. It is recommended that careful observations of patients undergoing phenelzine sulfate treatment be maintained until control of depression is achieved. If necessary, additional measures (ECT, hospitalization, etc) should be instituted.

All patients undergoing treatment with phenelzine sulfate should be closely followed for symptoms of postural hypotension. Hypotensive side effects have occurred in hypertensive as well as normotensive and hypotensive patients. Blood pressure usually returns to pretreatment levels rapidly when the drug is discontinued or the dosage is reduced.

Because the effect of phenelzine sulfate on the convulsive threshold may be variable, adequate precautions should be taken when treating epileptic patients.

Of the more severe side effects that have been reported with any consistency, hypomania has been the most common. This reaction has been largely limited to patients in whom disorders characterized by hyperkinetic symptoms coexist with, but are obscured by, depressive affect; hypomania usually appeared as depression improved. If agitation is present, it may be increased with phenelzine sulfate. Hypomania and agitation have also been reported at higher than recommended doses or following long-term therapy.

Phenelzine sulfate may cause excessive stimulation in schizophrenic patients; in manic-depressive states it may result in a swing from a depressive to a manic phase.

Phenelzine sulfate should be used with caution in diabetes mellitus; increased insulin sensitivity may occur. Requirements for insulin or oral hypoglycemics may be decreased.

MAO inhibitors, including phenelzine sulfate, potentiate hexobarbital hypnosis in animals. Therefore, barbiturates should be given at a reduced dose with phenelzine sulfate.

MAO inhibitors inhibit the destruction of serotonin and norepinephrine, which are believed to be released from tissue stores by rauwolfia alkaloids. Accordingly, caution should be exercised when rauwolfia is used concomitantly with an MAO inhibitor, including phenelzine sulfate.

There is conflicting evidence as to whether or not MAO inhibitors affect glucose metabolism or potentiate hypoglycemic agents. This should be kept in mind if phenelzine sulfate is administered to diabetics.
In this study we aimed to investigate the prevalence of SARS-CoV-2 infection in psoriasis patients, and outcomes of SARS-CoV-2 infection and associated risk factors. A cross-sectional survey was conducted from February 2023 to March 2023. Information was obtained with online questionnaire about psoriasis patients on demographic characteristics, clinical characteristics, SARS-CoV-2 infection and outcomes, vaccination, and routine protection against COVID-19. Logistic regression analysis was used to explore risk factors with SARS-CoV-2 infection and exacerbation of psoriasis. A total of 613 participants were recruited. 516 (84.2%) were infected, and associated factors were sex, working status, routine protection against COVID-19, COVID-19 vaccination, impaired nail, infection exacerbate psoriasis, and severity of psoriasis. Among the patients infected with SARS-CoV-2, 30 (5.8%) required hospitalization, 122 (23.6%) had psoriasis exacerbation due to SARS-CoV-2 infection, and associated factors were subtype of psoriasis, discontinuation of psoriasis treatment during SARS-CoV-2 infection, response following COVID-19 vaccination, and severity of psoriasis. Booster dose vaccination contributed a low probability of COVID-19 sequelae. COVID-19 vaccine's effectiveness was unsatisfactory, while booster dose vaccination reduced the occurrence of COVID-19 sequelae in psoriasis patients of Southwest China. Patients treated with psoriasis shown to be safe, without a higher incidence of SARS-CoV-2 infection or COVID-19hospitalization compared to untreated patients. Stopping treatment during SARS-CoV-2 infection led to psoriasis exacerbation, so psoriasis treatment could be continued except severe adverse reaction.
9-Hydroxyellipticine glycoside of formula (I) is prepd. by heating ellipticine glycoside deriv. of formula (II) with conc. hydrobromic acid aq. soln. for acidolysis. In the formulas, A is aldose residue or deoxyaldose residue; bond denoted by N(+)-A is glycoside bond of 2-N of ellipticine and 1-C atom of sugar; R1 is C1-3  alkyl or benzyl; B is acylated aldose residue where H atom of hydroxy gp. of sugar is substd. with C2-9 acyl, benzylated aldose residue where H atom of hydroxyl gp. of sugar is substd. with benzyl or acylated deoxyaldose residue where H atoms of hydroxy gp. of sugar are substd. with C2-9 acyl. (I) may be used as carcinostatic.